PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28677768-0	2017	Thromboxane A2 receptor antagonist SQ29548 suppresses the LPS-induced release of inflammatory cytokines in BV2 microglia cells via suppressing MAPK and NF-kappaB signaling pathways.	SQ 29548	35-42	thromboxane A2 receptor	Mus musculus	0-23	
27775054-0	2016	Thromboxane A2 receptor antagonist SQ29548 reduces ischemic stroke-induced microglia/macrophages activation and enrichment, and ameliorates brain injury.	SQ 29548	35-42	thromboxane A2 receptor	Mus musculus	0-23	
27775054-2	2016	We have previously shown that TXA2R antagonist SQ29548 attenuates BV2 microglia activation by suppression of ERK pathway, but its effect is not tested in vivo.	SQ 29548	47-54	thromboxane A2 receptor	Mus musculus	30-35	
27775054-9	2016	TXA2R antagonist SQ29548 inhibited ischemia-induced inflammatory response and furthermore reduced microglia/macrophages activation and ischemic/reperfusion brain injury.	SQ 29548	17-24	thromboxane A2 receptor	Mus musculus	0-5	
23741477-6	2013	Relaxation attenuated by LPC 20:4 and 18:2 was improved by indomethacin and SQ29548, a thromboxane A2 (TXA2)- receptor antagonist.	SQ 29548	76-83	thromboxane A2 receptor	Mus musculus	87-118	
25921923-8	2015	Notably, Up4A-induced aortic contraction was blunted by both TX synthase inhibitor ozagrel and TXA2 receptor (TP) antagonist SQ29548.	SQ 29548	125-132	thromboxane A2 receptor	Mus musculus	95-108	
11740157-5	2001	Indomethacin and SQ29548 (PGH2/TXA2 receptor antagonist) had no efffect in control, but inhibited myogenic tone in db/db mice.	SQ 29548	17-24	thromboxane A2 receptor	Mus musculus	31-44